02/16/2026
Russia has announced that its new cancer vaccine, “Enteromix,” reportedly achieved a 100% success rate in clinical trials and has been authorized for clinical use. Any claim of total effectiveness in cancer treatment quickly attracts worldwide attention because cancer encompasses many complex and diverse diseases.
In oncology, a “100% success rate” typically applies to a specific group of patients, cancer type, or stage, rather than representing a universal cure. Cancer vaccines may work by activating the immune system to recognize and destroy tumor cells or by targeting specific markers unique to cancer. Before such findings are widely accepted, thorough peer-reviewed research, independent confirmation, and long-term follow-up are necessary to verify safety and lasting effectiveness.
If independently confirmed, this could represent a significant breakthrough in cancer immunotherapy. However, until complete trial results are fully reviewed and validated by the global scientific community, cautious optimism is the most responsible way to interpret such broad medical claims.